{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:25Z","timestamp":1787584585884,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing data are available on the use and efficacy of rituximab (RTX) in patients with anti-muscle-specific tyrosine kinase (MuSK)-positive myasthenia gravis (MG), especially those steroid-dependent or unresponsive to traditional immunotherapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>We aimed to evaluate the clinical characteristics and treatment responses of adult patients with generalized anti-MuSK-positive MG treated with RTX.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively recruited 16 patients who were on RTX, between January 2010 and September 2023. RTX was given 1000\u00a0mg\/day intravenously twice, two weeks apart. Maintenance treatment was administered at intervals of 3\u20146\u00a0months based on clinical evaluation. The outcome was assessed by Myasthenia Gravis Foundation of America (MGFA) and Myasthenia Gravis Status and Treatment Intensity (MGSTI) scores. Additionally, anti-MuSK antibody levels were retested after treatment in all patients except one.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twelve patients were female. The mean age at disease onset was 35.3\u00a0\u00b1 17.3 years. The median duration between disease onset and RTX administration was 2.4 years (min-max: 0.5-36.5 years). The worst MGFA class before RTX was between IIIb-V. After RTX treatment, 81.3% of patients achieved MGFA minimal manifestations or better and MGSTI level 1 or better. Anti-MuSK antibodies became negative in 12 patients, while they remained positive in three. The changes in antibody levels seemed associated with clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RTX is an effective treatment in anti-MuSK-positive MG. Furthermore, our results support the inhibition of antibody production by RTX and we recommend monitoring anti-MuSK antibody titers to follow disease progression and treatment response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-024-03763-w","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:15:27Z","timestamp":1722485727000},"page":"2989-2994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis"],"prefix":"10.1007","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-0207","authenticated-orcid":false,"given":"Berin","family":"Inan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-8806","authenticated-orcid":false,"given":"Irem Gul","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-6979","authenticated-orcid":false,"given":"Can Ebru","family":"Bekircan-Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-6457","authenticated-orcid":false,"given":"Sevim","family":"Erdem-Ozdamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-2961","authenticated-orcid":false,"given":"Ersin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al. (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A et al. (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:660. https:\/\/doi.org\/10.3389\/fneur.2020.00660","journal-title":"Front Neurol"},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al. (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"3763_CR5","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86:255\u2013260","journal-title":"Yale J Biol Med"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Pu M, Chen D et al. (2021) Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis. Front Neurol 12:736190. https:\/\/doi.org\/10.3389\/fneur.2021.736190","journal-title":"Front Neurol"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G et al. (2020) Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis. Front Immunol 11:613. https:\/\/doi.org\/10.3389\/fimmu.2020.00613","journal-title":"Front Immunol"},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM et al. (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67:505\u2013507. https:\/\/doi.org\/10.1212\/01.wnl.0000228225.23349.5d","journal-title":"Neurology"},{"key":"3763_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14712598.2021.1889509","volume":"21","author":"ZA Siddiqi","year":"2021","unstructured":"Siddiqi ZA, Khan W, Hussain FS (2021) Rituximab in myasthenia gravis - where do we stand? Expert Opin Biol Ther 21:1013\u20131023. https:\/\/doi.org\/10.1080\/14712598.2021.1889509","journal-title":"Expert Opin Biol Ther"},{"key":"3763_CR10","doi-asserted-by":"publisher","unstructured":"Jordan A, Freimer M (2018) Recent advances in understanding and managing myasthenia gravis. F1000Res 7. https:\/\/doi.org\/10.12688\/f1000research.15973.1","DOI":"10.12688\/f1000research.15973.1"},{"key":"3763_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W et al. (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56:185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"3763_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al. (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian R, Zimprich F, Iglseder S et al. (2019) High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 266:699\u2013706. https:\/\/doi.org\/10.1007\/s00415-019-09191-6","journal-title":"J Neurol"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","volume":"5","author":"E Cortes-Vicente","year":"2018","unstructured":"Cortes-Vicente E, Rojas-Garcia R, Diaz-Manera J et al. (2018) The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol 5:710\u2013716. https:\/\/doi.org\/10.1002\/acn3.564","journal-title":"Ann Clin Transl Neurol"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE et al. (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262:1115\u20131119. https:\/\/doi.org\/10.1007\/s00415-014-7532-3","journal-title":"J Neurol"},{"key":"3763_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al. (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurology"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/nsn.nsn_197_21","volume":"39","author":"B Inan","year":"2022","unstructured":"Inan B, Bekircan-Kurt CE, Demiro\u011flu H et al. (2022) Autologous stem cell transplantation in a patient with refractory anti-MuSK-positive myasthenia gravis and familial mediterranean fever. Neurol Sci Neurophysiol 39:115\u2013118. https:\/\/doi.org\/10.4103\/nsn.nsn_197_21","journal-title":"Neurol Sci Neurophysiol"},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli A, Alboini PE, Damato V et al. (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412:82\u201389. https:\/\/doi.org\/10.1111\/nyas.13518","journal-title":"Ann N Y Acad Sci"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/mus.27233","volume":"63","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Yan C, Gu X et al. (2021) Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody. Muscle Nerve 63:824\u2013830. https:\/\/doi.org\/10.1002\/mus.27233","journal-title":"Muscle Nerve"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.27393","volume":"64","author":"CT Doughty","year":"2021","unstructured":"Doughty CT, Suh J, David WS et al. (2021) Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >\/=65 years old. Muscle Nerve 64:651\u2013656. https:\/\/doi.org\/10.1002\/mus.27393","journal-title":"Muscle Nerve"},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/NDT.S358851","volume":"18","author":"X Meng","year":"2022","unstructured":"Meng X, Zeng Z, Wang Y et al. (2022) Efficacy and Safety of low-dose rituximab in anti-MuSK myasthenia gravis patients: a retrospective study. Neuropsychiatr Dis Treat 18:953\u2013964. https:\/\/doi.org\/10.2147\/NDT.S358851","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","volume":"14","author":"A Vesperinas-Castro","year":"2023","unstructured":"Vesperinas-Castro A, Cortes-Vicente E (2023) Rituximab treatment in myasthenia gravis. Front Neurol 14:1275533. https:\/\/doi.org\/10.3389\/fneur.2023.1275533","journal-title":"Front Neurol"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"725700","DOI":"10.3389\/fneur.2021.725700","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Song Z, Wu M et al. (2021) Efficacy and safety of immunotherapies in refractory myasthenia gravis: a systematic review and meta-analysis. Front Neurol 12:725700. https:\/\/doi.org\/10.3389\/fneur.2021.725700","journal-title":"Front Neurol"},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","volume":"311","author":"S Jing","year":"2017","unstructured":"Jing S, Song Y, Song J et al. (2017) Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. J Neuroimmunol 311:14\u201321. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.021","journal-title":"J Neuroimmunol"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al. (2020) Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77:974\u2013981. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al. (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/CND.0000000000000420","volume":"24","author":"JI Castiglione","year":"2022","unstructured":"Castiglione JI, Rivero AD, Barroso F et al. (2022) Long-term remission with low-dose rituximab in myasthenia gravis: a retrospective study. J Clin Neuromuscul Dis 24:18\u201325. https:\/\/doi.org\/10.1097\/CND.0000000000000420","journal-title":"J Clin Neuromuscul Dis"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"116690","DOI":"10.1016\/j.jns.2020.116690","volume":"411","author":"T Litchman","year":"2020","unstructured":"Litchman T, Roy B, Kumar A et al. (2020) Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. J Neurol Sci 411:116690. https:\/\/doi.org\/10.1016\/j.jns.2020.116690","journal-title":"J Neurol Sci"},{"key":"3763_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"Diaz-Manera J, Martinez-Hernandez E, Querol L et al. (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189\u2013193. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982","journal-title":"Neurology"},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","volume":"29","author":"RH Roda","year":"2019","unstructured":"Roda RH, Doherty L, Corse AM (2019) Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Neuromuscul Disord 29:554\u2013561. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.002","journal-title":"Neuromuscul Disord"},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fneur.2020.00981","volume":"11","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, Antozzi C (2020) From traditional to targeted immunotherapy in myasthenia gravis: prospects for research. Front Neurol 11:981. https:\/\/doi.org\/10.3389\/fneur.2020.00981","journal-title":"Front Neurol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03763-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:24:42Z","timestamp":1734956682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03763-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03763-w","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional and local ethics committees approved the study and waived the requirement for informed consent from patients (2021\/05\u201305\u2014KA21021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}